Abstract
Disrupting microtubule dynamics with spindle poisons activates the spindle-assembly checkpoint (SAC) and induces mitotic cell death. However, mitotic exit can occur prematurely without proper chromosomal segregation or cytokinesis by a process termed mitotic slippage. It remains controversial whether mitotic slippage increases the cytotoxicity of spindle poisons or the converse. Altering the SAC induces either mitotic cell death or mitotic slippage. While knockout of MAD2-binding protein p31comet strengthened the SAC and promoted mitotic cell death, knockout of TRIP13 had the opposite effect of triggering mitotic slippage. We demonstrated that mitotic slippage prevented mitotic cell death caused by spindle poisons, but reduced subsequent long-term survival. Weakening of the SAC also reduced cell survival in response to spindle perturbation insufficient for triggering mitotic slippage, of which mitotic exit was characterized by displaced chromosomes during metaphase. In either mitotic slippage or mitotic exit with missegregated chromosomes, cell death occurred only after one cell cycle following mitotic exit and increased progressively during subsequent cell cycles. Consistent with these results, transient inhibition of the SAC using an MPS1 inhibitor acted synergistically with spindle perturbation in inducing chromosome missegregation and cytotoxicity. The specific temporal patterns of cell death after mitotic exit with weakened SAC may reconcile the contradictory results from many previous studies.
Similar content being viewed by others
Introduction
Classic spindle poisons that either attenuate depolymerization (e.g. taxanes) or polymerization (e.g. vinca alkaloid) of microtubules are among the most useful chemotherapeutic agents available. Disrupting microtubule dynamics prevents proper attachment of microtubules to kinetochores, resulting in the activation of the spindle-assembly checkpoint (SAC) and mitotic arrest1.
Despite the widespread use of spindle poisons as front-line chemotherapeutic agents, precisely how they exert their cytotoxic effects remains perplexing. This is because the fate of cells after protracted mitotic block varies greatly between different cell lines as well as between individual cells from the same cell line2. The cell fate appears to be determined by two stochastically competing networks, one controlling mitotic cell death and the other mitotic slippage. On the one hand, mitotic cell death is believed to be caused by an accumulation of apoptotic activators and/or a loss of apoptotic inhibitors during mitosis3. On the other hand, it is possible for cells to exit mitosis into interphase without proper chromosome segregation and cytokinesis by a process termed mitotic slippage. The current paradigm states that an underlying mechanism of mitotic slippage is a slow degradation of cyclin B1 during mitotic arrest4.
Although mitotic slippage is a major outcome after antimitotic drug treatment, whether it promotes or reduces cytotoxicity remains a contentious issue. On the one hand, mitotic slippage interrupts the mitotic arrest and is expected to attenuate mitotic cell death. On the other hand, the tetraploid G1 cells generated after mitotic slippage are expected to be less fit to propagate than normal cells. The tetraploid DNA contents and supernumerary centrosomes generated after mitotic slippage can be further duplicated during the subsequent cell cycle and induce genome instability5.
An impressive number of studies in the literature contain experimental evidence either supporting that mitotic slippage increases the cytotoxicity of antimitotic drugs or the converse. On the one hand, many studies using diverse cell lines and methods of triggering mitotic slippage concluded that mitotic slippage limits the effectiveness of antimitotic drugs and promotes drug resistance. Examples include mitotic slippage induced by weakening of the SAC using small interfering RNAs (siRNAs) against MAD2 or BUBR16,7,8, MAD2-targeting microRNA9, overexpression of p31comet 10, 11 or MPS1 inhibitors12. Other approaches including expressing CDC613, inhibiting aurora kinases14,15,16 or activating WEE117 also reduced cytotoxicity of antimitotic drugs by inducing mitotic slippage. On the other hand, a number of studies indicate that mitotic slippage increases the effectiveness of antimitotic drugs. Examples include forcing mitotic slippage using CDK1 inhibitor18,19,20, aurora kinase inhibitor21, histone deacetylase inhibitor22, hyperthermia23, DNA damage24, siRNAs against survivin25 or BUBR126, or inhibition of other targets27.
Why different studies on the effects of mitotic slippage, often using similar approaches, would give rise to such ambiguities and contradictions? If there are large gaps in our knowledge regarding the effects of mitotic slippage, even less is known about smaller scale of chromosomal instability such as missegregation of a small number of chromosomes. We suspect one possible explanation is the uncertainty of when cell fate should be measured after mitotic slippage. Given that mitotic slippage abolishes mitotic cell death, sampling shortly after mitotic slippage would result in an apparent increase in survival. The length of mitotic block could also affect post-exit cell death, presumably due to the accumulation of cell death signals during the arrest15. Furthermore, chemicals used to induce mitotic slippage may have non-specific effects and reduce viability during the subsequent interphase. Given these limitations, it is critical to understand precisely when cell death occurs after mitotic slippage, preferably inducing mitotic slippage without the use of chemicals. Here we used isogenic cell lines with different SAC status to study mitotic slippage more comprehensively. We monitored the events from immediately following mitotic slippage to over the next several days.
Materials and methods
Cell culture
The HeLa used in this study was a clone that expressed the tTA tetracycline transactivator28. HCT116 (colorectal carcinoma) was a gift from Bert Vogelstein (The Johns Hopkins University). TRIP13-knockout (TRIP13KO) cells, TRIP13KO-expressing FLAG-TRIP13 and p31KO were generated as previously described29. TRIP13KO-expressing auxin-inducible degron (AID)-TRIP13 and TIR1 were generated as previously described30. Cells were propagated in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) calf serum (for HeLa) or foetal bovine serum (for HCT116) and 50 U/ml of penicillin–streptomycin (Life Technologies, Carlsbad, CA, USA). Cells were cultured in humidified incubators at 37 °C with 5% CO2. Cell viability was assessed using trypan blue exclusion assay.
Unless stated otherwise, cells were treated with the following reagents at the indicated final concentration: doxycycline hydrochloride (Dox) (2 µg/ml), indole-3-acetic acid (IAA) (50 µg/ml), paclitaxel (PTX) (125 ng/ml), thymidine (2 mM) (Sigma-Aldrich, St. Louis, MO, USA), AZ3146 (0.5 µM), MG132 (10 µM) (Selleck Chemicals, Houston, TX, USA), nocodazole (NOC) (100 ng/ml), RO3306 (10 µM) and Z-VAD-FMK (20 µM) (Enzo Life Sciences, Farmingdale, NY, USA).
Clonogenic survival assays
The indicated number of cells were plated onto 60-mm plates and allowed to grow overnight. The medium was then supplemented with vehicle alone or the indicated drugs for 24 h. Cells were washed gently with phosphate-buffered saline and fresh medium was replenished. After 2 weeks (unless stated otherwise, neither the drugs nor the medium was replenished over the period), colonies were fixed with methanol:acetic acid (v/v 2:1), followed by staining with 2% crystal violet. The number of colonies was quantified using Quantity One (Bio-Rad, Hercules, CA, USA).
Cell cycle synchronization
Cell cycle synchronization using single or double thymidine method was performed as described31. Mitotic cells were synchronized using thymidine synchronization followed by NOC and isolated with mechanical shake-off as described previously31.
Live-cell imaging and microscopy
Cells were seeded onto 24-well cell culture plates and placed onto a TE2000E-PFS microscope (Nikon, Tokyo, Japan) equipped with a SPOT BOOST EMCCD camera (SPOT Imaging Solutions, Sterling Heights, MI, USA) and an INU-NI-F1 temperature, humidity and CO2 control chamber (Tokai Hit, Fujinomiya, Shizuoka, Japan). Images were captured every 5 min (for 24 h imaging) or every 10 min (for >48 h imaging). Data acquisition was carried out with the Metamorph 7.5 software (Molecular Devices, Sunnyvale, CA, USA) and analysis was carried out manually using the ImageJ 1.52e software (National Institutes of Health). The fates of at least 50 cells (indicated in the Figures) were tracked through the entire imaging period for each condition. Following mitosis, one of the daughter cells (if there were more than one) was randomly chosen and tracked further.
Flow cytometry analysis
Flow cytometry analysis after propidium iodide staining was performed as described previously32 except that a Coulter Epics XL flow cytometer was used (Beckman Coulter, Brea, CA, USA).
Antibodies and immunological methods
Antibodies against β-actin (Sigma-Aldrich), phosphor-histone H3Ser10, TRIP13 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and cleaved PARP1(Asp214) (BD Transduction Laboratories, Franklin Lakes, NJ, USA) were obtained from the indicated suppliers. Antibodies against cyclin B1 were gifts from Julian Gannon (Cancer Research UK). Immunoblotting was performed as previously described29.
Statistical analysis
Two-tailed Student’s t test was used to calculate statistical significance. P < 0.05 was considered statistically significant.
RESULTS
Altering the SAC induces cell death either during mitosis or after mitotic slippage
The effectiveness of the SAC is believed to influence the outcome of spindle poison-mediated mitotic block (Fig. 1a). To strengthen the SAC without the use of chemical inhibitors, we used cells deficient in p31comet, which are impaired in turning off the SAC29. Wild type (WT) or p31comet-deficient HeLa cells expressing histone H2B-GFP were incubated with NOC and subjected to live-cell imaging (Fig. 1b). The relatively low concentration of NOC used in this experiment induced a delay without blocking mitosis in WT cells. By contrast, NOC induced a more prolonged mitosis in p31comet-deficient cells, ultimately resulting in mitotic cell death in the majority of the cells. Consistent with these results, clonogenic survival was reduced by NOC more significantly in p31comet-deficient cells than in WT cells (Fig. 1c). Similar results were obtained using WT and p31comet-deficient HCT116 cells, indicating that the effect was not limited to one cell line (Fig. S1).
We next performed the converse experiments by prematurely inactivating the SAC. As the length of mitotic block could affect post-exit cell death15, synchronized culture was used to minimize the duration of NOC treatment (Fig. 2a). Note that a higher concentration of NOC was used compared to the previous experiment to induce a complete block in mitosis. We first uncoupled the SAC using an inhibitor of MPS1 (MPS1i), which induced cyclin B1 degradation (thereby inactivating CDK1) and mitotic exit as indicated by dephosphorylation of histone H3Ser10 (Fig S2). Alternatively, CDK1 was directly inactivated using the CDK1 inhibitor RO3306 (CDK1i). In both cases, mitotic exit occurred rapidly without chromosomal segregation or cytokinesis. Importantly, clonogenic survival was significantly reduced after mitotic slippage in comparison to cells released from the mitotic block (Fig. 2b, c).
The time of cell death after mitotic slippage was visualized directly using live-cell imaging (Fig. 2d). Within the 48 h imaging period, nearly all WT cells were able to complete three cell cycles after they were released from NOC-mediated arrest. By contrast, although the majority of cells remained viable during the cell cycle immediately post-mitotic slippage, cell death increased steadily after the subsequent mitosis (Fig. 2d, bottom panel).
As a prevailing view is that mitotic slippage increases resistance to spindle poisons (see Introduction), we further explored if cells surviving mitotic slippage have different sensitivity to spindle poisons or further rounds of mitotic slippage. Mitotic slippage was induced by treating cells with NOC followed by CDK1i. The surviving cells were then pooled and expanded. These cells displayed similar sensitivity to NOC as the WT cells (data not shown). Moreover, they were killed by a second round of mitotic slippage to a similar extent as WT cells (Fig. 2e), indicating that cells surviving mitotic slippage did not develop further resistance to spindle poisons.
A caveat of the above experiments is that we cannot exclude the possibility that cell death occurred after CDK1i or MPS1i treatment was caused by the toxicity of the chemicals in addition to mitotic slippage. Consistent with that, CDK1i and MPS1i promoted cell death at different rates post-mitotic slippage (Fig. 2d). To circumvent this, we made use of cells engineered to have a defective SAC. Impaired SAC, however, undermines viability even in the unperturbed cell cycle. For example, depletion of MAD2 results in inviability in HeLa30 or mouse models33. TRIP13 is involved in converting MAD2 from the active C-MAD2 to the inactive O-MAD2 conformation29. Although the newly synthesized O-MAD2 in TRIP13-deficient cells is sufficient to support unperturbed cell cycle, the predominantly C-MAD2 environment is insufficient to enable the SAC after challenged with NOC30. Individuals with loss-of-function mutations in TRIP13 show dysregulated SAC and are predisposed to Wilms’ tumour34. In contrast to HeLa cells, which could be arrested in mitosis with NOC, TRIP13KO cells failed to be trapped in mitosis (Fig. 3a). Importantly, apoptosis occurred in WT cells, but not in TRIP13KO cells (as indicated by cleavage of PARP1). Both mitotic block and cell death could be rescued by re-introducing FLAG-TRIP13 into the TRIP13KO cells.
The evasion of mitotic cell death in TRIP13KO cells was further confirmed using flow cytometry analysis (Fig. 3b). While WT cells were arrested in G2/M after being challenged with NOC for 24 h, TRIP13KO cells also contained 8N DNA contents, indicating they underwent mitotic slippage followed by DNA replication. As a portion of NOC-treated WT cells underwent apoptosis (Fig. 3a, b), a pan-caspase inhibitor was included to confirm that WT cells did not undergo mitotic slippage and DNA replication in the absence of apoptosis (Fig. 3c).
Mitotic cell death induced with another spindle poison, PTX, was also abolished in TRIP13KO cells, indicating that the effects were not limited to NOC (Fig. S3). We further performed similar analyses using TRIP13KO cells generated from HCT116 (Fig. S4a), confirming that the abolition of mitotic cell death by TRIP13 deficiency was not cell line-specific (Fig. S5).
Finally, directly observing mitotic slippage using live-cell imaging revealed that while WT cells were able to be trapped in mitosis by NOC (mean ~16 h), TRIP13KO cells rapidly underwent mitotic slippage (Fig. 4a). An example is shown in Supplemental video 1. The mitotic block was restored in TRIP13KO cells with recombinant TRIP13. Similar results were obtained using PTX as a mitotic blocker (Fig. S6b). Collectively, these data demonstrated that mitotic slippage prevents mitotic cell death caused by spindle poisons, but reduces subsequent long-term survival.
Cell death occurs only after one cell cycle following mitotic slippage
The above data indicate that SAC deficiency promoted short-term survival (up to a few cell cycles) following treatment with NOC or PTX (Fig. 4b, Fig. S6c). Paradoxically, long-term viability (up to a few weeks) was reduced in SAC-deficient cells (Fig. 4c). To determine more precisely the timing of cell death, synchronized cells were treated with NOC followed by live-cell imaging spanning several cell cycles (Fig. 4d). As before, while WT cells could be arrested in mitosis with NOC, TRIP13KO cells underwent rapid mitotic slippage. After washing out the NOC, WT cells underwent about three rounds of cell cycle without exhibiting significant level of cell death. Interestingly, tetraploid TRIP13KO cells remained viable during the first cell cycle post-mitotic slippage. Cell death only started to accumulate after the first mitosis following mitotic slippage. As anticipated, the majority of the mitoses after mitotic slippage were characterized by abnormalities, including multipolar mitosis and chromosome missegregation (>80%). Cell death, however, occurred predominantly during interphase and at an approximately constant rate.
The above data suggested that mitotic slippage-mediated whole-genome imbalance was not the main cause of cell death. Indeed, less cell death occurred in TRIP13KO cells if NOC was applied continuously (mitotic slippage also occurred in subsequent mitoses) compared to when NOC was removed after mitotic slippage as detected by both live-cell imaging (compare Fig. 4d and Fig. S6a, respectively) and the appearance of cleaved PARP1 (Fig. 4e).
Collectively, these results indicate that while mitotic slippage prevents cell death through the first cell cycle, cell death occurs progressively during subsequent cell cycles.
Defective SAC also reduces cell survival in response to spindle perturbation insufficient for mitotic slippage
Given that the effective concentration of spindle poisons achieved in vivo is unlikely to completely disrupt spindles or induce a prolonged mitotic arrest (reviewed in ref. 3), we next studied the temporal dependency of cytotoxicity after SAC-deficient cells were treated with low concentrations of spindle poisons. We found that 11 ng/ml of NOC induced neither a significant change in cell cycle profile (Fig. 3b) nor any mitotic slippage as observed using live-cell imaging (see later) in SAC-proficient or -deficient cells. Nonetheless, incubation of TRIP13KO cells with this concentration of NOC reduced clonogenic survival by >90% (compared to ~50% in WT cells) (Fig. 5a). TRIP13-deficient HCT116 cells were also more sensitive to NOC than WT cells (Fig. S7a). Sensitivity to a sublethal dose of PTX was likewise increased by TRIP13 deficiency (Fig. S7b).
Although WT and TRIP13KO cells were isogenic, it is conceivable that additional genetic or epigenetic changes may have occurred during the generation of these cell lines. To ensure that the effects of spindle poisons were due to TRIP13 deficiency alone, we also used TRIP13KO cells expressing AID-tagged TRIP13 to conditionally inactivate TRIP13. AID-tagged proteins are degraded rapidly in response to plant auxin (or IAA) in cells expressing the ubiquitin ligase SCFTIR1 35. Consequently AID-TRIP13 could be shut off in the presence of IAA and doxycycline (the AID-TRIP13 was also under the control of a Tet-Off promoter) (Fig S4b). Figure 5b shows that less number of colonies were formed after AID-TRIP13 degradation, confirming that SAC-deficient cells were more sensitive to low concentrations of NOC.
To determine when cell death was initiated, live-cell imaging was used to analyse cells both during NOC exposure and at different periods after washing (Fig. 6a). During incubation with NOC (24 h), cell death occurred exclusively in WT cells, but not TRIP13KO cells. The majority of cell death occurred during mitosis (>90%), which was substantially longer than unperturbed mitosis (Fig. S8). In marked contrast, TRIP13KO cells displayed negligible level of cell death in the presence of NOC as well as during the first cell cycle after release (Fig. S8). Significantly, more cell death occurred in TRIP13KO cells than in WT cells over the subsequent cell cycles (of which >90% occurred during interphase) (Fig. 6a). The switch in the level of cytotoxicity between SAC-proficient and -deficient cells during and after NOC treatment was also reflected in the total cell number. In the presence of NOC, there was an increase in cell number in TRIP13KO cells, but not in WT cells. WT and TRIP13KO cells then proliferated at the same rate over the next 48 h. Finally, WT cells proliferated more rapidly than TRIP13KO cells over the following 48 h, reflecting the increase in cytotoxicity in TRIP13KO cells at later cell cycles (Fig. 6a).
An interesting question is whether the sensitization to spindle perturbation was due to defective SAC during the initial period of NOC challenge or also over the subsequent cell cycles. To demarcate these possibilities, AID-TRIP13 was turned off either for only the period of NOC treatment (24 h) or for the entire period of clonogenic formation (14 days). Figure 6b shows that AID-TRIP13 was able to re-accumulate after Dox and IAA were removed. Moreover, a similar number of colonies were formed irrespective of whether TRIP13 was present or absent during the subsequent recovery period, suggesting that the lack of SAC during spindle perturbation is more critical for the cytotoxicity than the subsequent cell cycles.
Although partial spindle perturbation did not induce mitotic slippage in TRIP13KO cells, mitosis was characterized by chromosome missegregation. More than 60% of mitoses contained displaced chromosomes during metaphase (Fig. 7a, Fig. S8), which frequently resulted in micronucleation in the daughter cells (Fig. 7b). An example is shown in Supplemental video 2.
Collectively, these results indicate that weakening of the SAC promotes either mitotic slippage or chromosome missegregation, depending on the concentration of spindle poison used. Both result in cell survival over the first cell cycle, but progressively increase in cell death during subsequent cell cycles.
Chemical inhibition of SAC promotes chromosomal missegregation and reduced viability
The above results showed that the SAC requires to be inactivated only transiently during spindle perturbation to promote subsequent cell death (Fig. 6b). Given its clinical implication, we further characterized if transient inhibition of the SAC with small chemical inhibitors could recapitulate the chromosome missegregation and the temporal pattern of cytotoxicity as SAC-deficient cells. Inhibition of MPS1 with RNA interference or inhibitors increases the sensitivity to spindle poisons36. Using live-cell imaging analysis, we found that MPS1i reduced the short-term cell death caused by NOC (Fig. 8a). Note that MPS1i did not trigger mitotic slippage in the presence of the relatively low concentration of NOC. However, MPS1i and NOC together reduced long-term clonogenic survival more significantly than the individual drug alone (Fig. 8b). MPS1i treatment correlated with an increase in displaced chromosomes during metaphase (Fig. 8c) and micronuclei in daughter cells (Fig. 8d). An example in shown in Supplemental video 3. Collectively, these results indicate that chemical inhibition of the SAC acts synergistically with spindle perturbation in inducing chromosome missegregation and cytotoxicity.
DISCUSSION
In this study, we evaluated the temporal regulation of cell death following aberrant mitosis, intending to reconcile the number of conflicting reports concerning the effect of SAC on the effectiveness of spindle poisons. SAC-hyperactive (p31KO) or SAC-deficient (TRIP13KO) cells were used in the study, thereby avoiding possible non-specific effects associated with chemical inhibitors. In SAC-hyperactive p31KO cells, mitotic cell death became the predominant cell fate following exposure to even low concentrations of spindle poisons (Fig. 1). By contrast, SAC-deficient TRIP13KO cells prevented mitotic cell death by accelerating mitotic slippage or mitotic exit with chromosome missegregation.
Within the first 48 h treatment with spindle poisons, cell death was reduced in cells undergoing mitotic slippage compared to those arrested continuously in mitosis (Fig. 4b). During the subsequent several cell cycles, the continued presence of spindle poisons resulted in mitotic slippage in the subsequent mitoses, reducing the overall cell death (Fig. 4e, Fig. S6a). But if spindle poisons were removed after mitotic slippage, cell death began to accumulate after the following mitosis, occurring mainly during interphase (Fig. 4d, e). As the spindle poisons were already removed, the cell death was independent on the direct toxicity of the spindle poisons during interphase37. This was consistent with the diminishing long-term cell survival after mitotic slippage (Fig. 4c). The progressive reduction in viability was likely to be due to chromosomal instability caused by the subsequent uncoordinated centrosome cycle and multipolar mitosis (Fig. 4d). In addition, DNA damage can accumulate during the aberrant mitosis38, 39 and may be responsible for some of the apoptosis during the subsequent interphase40. The time involved in switching from abrogating cell death immediately post-mitotic slippage to increasing cell death over the subsequent cell cycles may reconcile the contradictory results obtained in different studies in the literature (see Fig. 8e for model).
In spite of having an extra set of chromosomes, post-mitotic slippage cells remained viable during the following cell cycle. Indeed, stable tetraploid cells can be generated from some cancer cell lines by treating them transiently with spindle poisons41,42,43. It is likely that mitotic slippage may not be an effective strategy in killing cancer cells that have mechanisms that can cluster or inactivate supernumerary centrosomes.
Interestingly, TRIP13 deficiency also promoted cell death in the presence of concentrations of spindle poisons insufficient for causing mitotic slippage (Fig. 5, Fig. S7). Although cell division could be completed, mitosis was shortened (Fig. S8) and displayed a significant increase in chromosome missegregation (Fig. 7). Micronucleation was also frequently observed in the daughter cells (Fig. 7). Micronuclei can be spontaneously generated in HeLa cells through multiple mechanisms, including lagging chromosomes during anaphase (the majority of cases), displaced chromosomes in metaphase and chromosomal bridges44. In the case of partial spindle disruption and weakened SAC, the origin of the micronucleation appears to be mainly from displaced chromosomes in metaphase (Fig. 7). Other studies indicated that chromosome missegregation caused by mitotic defects including reduction of MPS1 or BUBR145, CENP-E46 or Spindly47 also induce cytotoxicity.
It is unclear why similar to mitotic slippage, most of the daughter cells survived the first cell cycle after partial chromosome missegregation in SAC-deficient cells. Cell death only progressively increased in the subsequent cell cycles (Fig. S8). It is possible that cancer cells such as HeLa can tolerate missegregation of both the entire genome and a small number of chromosomes for one cell cycle. Why cells with missegregation of a small number of chromosomes started to die in subsequent cell cycles is more difficult to explain. One possibility is that the presence of micronuclei can be source of further genome instability such as through chromothripsis.
An implication is that the different effectiveness of SAC in cancer cells may affect the outcome of spindle poison therapies. This is an important issue because in addition to spindle poisons, other emerging anticancer chemicals targeting mitotic regulators such as Aurora kinases, polo-like kinases or kinesin Eg5 (KIF11) also act by triggering protracted mitotic arrest. Consistent with the results that SAC only needed to be turned off transiently for synergism with spindle poisons (Fig. 6b), inhibiting MPS1 transiently with the inhibitor AZ3146 sensitized cells to spindle poisons (Fig. 8). Cell death appears to be caused by a similar mechanism as in SAC-deficient cells, characterized by chromosome missegregation and micronucleation (Fig. 8). These results are consistent with studies using other MPS1 inhibitors and spindle poisons48,49,50. It is possible that in addition to the components described here, other components of the SAC can also be clinically relevant drug targets.
References
Gascoigne, K. E. & Taylor, S. S. How do anti-mitotic drugs kill cancer cells? J. Cell Sci. 122, 2579–2585 (2009).
Gascoigne, K. E. & Taylor, S. S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14, 111–122 (2008).
Haschka, M., Karbon, G., Fava, L. L. & Villunger, A. Perturbing mitosis for anti-cancer therapy: is cell death the only answer. EMBO Rep. 19, e45440 (2018).
Brito, D. A. & Rieder, C. L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 16, 1194–1200 (2006).
Storchova, Z. & Kuffer, C. The consequences of tetraploidy and aneuploidy. J. Cell Sci. 121, 3859–3866 (2008).
Chin, G. M. & Herbst, R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol. Cancer Ther. 5, 2580–2591 (2006).
Sudo, T., Nitta, M., Saya, H. & Ueno, N. T. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 64, 2502–2508 (2004).
Prencipe, M. et al. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. Br. J. Cancer 101, 1900–1908 (2009).
Tambe, M. et al. Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells’ sensitivity to paclitaxel. Oncotarget 7, 12267–12285 (2016).
Ma, H. T., Chan, Y. Y., Chen, X., On, K. F. & Poon, R. Y. Depletion of p31comet protein promotes sensitivity to antimitotic drugs. J. Biol. Chem. 287, 21561–21569 (2012).
Habu, T. & Matsumoto, T. p31(comet) inactivates the chemically induced Mad2-dependent spindle assembly checkpoint and leads to resistance to anti-mitotic drugs. + 2, 562 (2013).
Haschka, M. D. et al. The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest. Nat. Commun. 6, 6891 (2015).
He, Y. et al. Cell division cycle 6 promotes mitotic slippage and contributes to drug resistance in paclitaxel-treated cancer cells. PLoS ONE 11, e0162633 (2016).
Nair, J. S. & Schwartz, G. K. MLN-8237: a dual inhibitor of aurora A and B in soft tissue sarcomas. Oncotarget 7, 12893–12903 (2016).
Bekier, M. E., Fischbach, R., Lee, J. & Taylor, W. R. Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol. Cancer Ther. 8, 1646–1654 (2009).
Marxer, M., Ma, H. T., Man, W. Y. & Poon, R. Y. p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases. Oncogene 33, 3550–3560 (2014).
Visconti, R. et al. The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs. Cell Death Differ. 22, 1551–1560 (2015).
Xiao, J. et al. Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxel-treated HepG2 cells. Neoplasma 61, 41–47 (2014).
Sakurikar, N., Eichhorn, J. M., Alford, S. E. & Chambers, T. C. Identification of a mitotic death signature in cancer cell lines. Cancer Lett. 343, 232–238 (2014).
Chan, Y. W. et al. CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis. Cell Cycle 7, 1449–1461 (2008).
Salmela, A. L. et al. Novel pyrimidine-2,4-diamine derivative suppresses the cell viability and spindle assembly checkpoint activity by targeting Aurora kinases. Carcinogenesis 34, 436–445 (2013).
Dowling, M. et al. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol. Ther. 4, 197–206 (2005).
Giovinazzi, S., Bellapu, D., Morozov, V. M. & Ishov, A. M. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy. Cell Cycle 12, 2598–2607 (2013).
Bukowska, B., Rogalska, A., Forma, E., Brys, M. & Marczak, A. Why a combination of WP 631 and Epo B is an improvement on the drugs singly—involvement in the cell cycle and mitotic slippage. Asian Pac. J. Cancer Prev. 17, 1299–1308 (2016).
Asraf, H., Avunie-Masala, R., Hershfinkel, M. & Gheber, L. Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the Kinesin-5 inhibitor monastrol. PLoS ONE 10, e0129255 (2015).
Lee, E. A. et al. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol. Cancer Ther. 3, 661–669 (2004).
Riffell, J. L., Zimmerman, C., Khong, A., McHardy, L. M. & Roberge, M. Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle 8, 3025–3038 (2009).
Yam, C. H., Siu, W. Y., Lau, A. & Poon, R. Y. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. J. Biol. Chem. 275, 3158–3167 (2000).
Ma, H. T. & Poon, R. Y. TRIP13 regulates both the activation and inactivation of the spindle-assembly checkpoint. Cell Rep 14, 1086–1099 (2016).
Ma, H. T. & Poon, R. Y. C. TRIP13 functions in the establishment of the spindle assembly checkpoint by replenishing O-MAD2. Cell Rep 22, 1439–1450 (2018).
Ma, H. T. & Poon, R. Y. Synchronization of HeLa cells. Methods Mol. Biol. 761, 151–161 (2011).
Siu, W. Y., Arooz, T. & Poon, R. Y. Differential responses of proliferating versus quiescent cells to adriamycin. Exp. Cell Res. 250, 131–141 (1999).
Schvartzman, J. M., Sotillo, R. & Benezra, R. Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat. Rev. Cancer 10, 102–115 (2010).
Yost, S. et al. Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. Nat. Genet. 49, 1148–1151 (2017).
Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. Nat. Methods 6, 917–922 (2009).
Jemaa, M. et al. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death Differ. 20, 1532–1545 (2013).
Field, J. J., Kanakkanthara, A. & Miller, J. H. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg. Med. Chem. 22, 5050–5059 (2014).
Dalton, W. B., Nandan, M. O., Moore, R. T. & Yang, V. W. Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res. 67, 11487–11492 (2007).
Quignon, F. et al. Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrity in mammalian cells. Oncogene 26, 165–172 (2007).
Zhu, Y., Zhou, Y. & Shi, J. Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle. Cell Cycle 13, 1756–1764 (2014).
Hau, P. M., Siu, W. Y., Wong, N., Lai, P. B. & Poon, R. Y. Polyploidization increases the sensitivity to DNA-damaging agents in mammalian cells. FEBS Lett. 580, 4727–4736 (2006).
Yaguchi, K. et al. Uncoordinated centrosome cycle underlies the instability of non-diploid somatic cells in mammals. J. Cell Biol. 217, 2463–2483 (2018).
Jemaa, M. et al. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. Oncotarget 7, 885–901 (2016).
Rao, X. et al. Multiple origins of spontaneously arising micronuclei in HeLa cells: direct evidence from long-term live cell imaging. Mutat. Res. 646, 41–49 (2008).
Janssen, A., Kops, G. J. & Medema, R. H. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc. Natl. Acad. Sci. USA 106, 19108–19113 (2009).
Ohashi, A. et al. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat. Commun. 6, 7668 (2015).
Silva, P. M. et al. Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel. Cancer Lett. 394, 33–42 (2017).
Choi, M. et al. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability. Br. J. Pharmacol. 174, 1810–1825 (2017).
Tannous, B. A. et al. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J. Natl. Cancer. Inst. 105, 1322–1331 (2013).
Maia, A. R. R. et al. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. Br. J. Cancer 118, 1586–1595 (2018).
Acknowledgements
This work was supported in part by grants from the Research Grants Council (16100017 to H.T.M., 16100417 and T12-704/16-R to R.Y.C.P.), Health and Medical Research Fund (04153526 to H.T.M.) and Innovation and Technology Commission (ITCPD/17-9 to R.Y.C.P.).
Author information
Authors and Affiliations
Contributions
X.Z., W.K.X., T.M.L., H.T.M. and R.Y.C.P. conceived the project and designed experiments. X.Z., W.K.X., T.M.L. and H.T.M. carried out experiments. X.Z., W.K.X., T.M.L., H.T.M. and R.Y.C.P. analysed the data and wrote the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by S. He
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zeng, X., Xu, W.K., Lok, T.M. et al. Imbalance of the spindle-assembly checkpoint promotes spindle poison-mediated cytotoxicity with distinct kinetics. Cell Death Dis 10, 314 (2019). https://doi.org/10.1038/s41419-019-1539-8
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-019-1539-8
- Springer Nature Limited
This article is cited by
-
Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer
Nature Communications (2021)